MRMuhammad Haseeb Ul Rasool

Muhammad Haseeb Ul Rasool

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Muhammad Haseeb Ul Rasool has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term prognostic significance of negative CT-derived fractional flow reserve in patients with stable CAD: A meta-analysis of reconstructed time-to-event data

    by Roozbeh Narimani-Javid, Kiarash Tavakoli, Parham Dastjerdi, Bahar Parastooei, Fatemeh Najafinezhad, Mona Aghaei, Minoo Javadi, Muhammad Haseeb Ul Rasool, Namvar Movahedi, Amro Alsaid, et al.


  • Open Access

    Efficacy and outcomes of inclisiran in the management of homozygous and heterozygous familial hypercholesterolemia: a systematic review and meta-analysis

    by Zaraq Mbbs Khan, Ajeet Mbbs Singh, Muhammad Mbbs Haseeb Ur Rasool, Nimra Mbbs Qasim, Muhammad Mbbs Yafaa Naveed Chaudhary, Saif Mbbs Syed, Monazza Mbbs Riaz, Wajih Mbbs Rehman, Ihtiham Mbbs Rehman, Rabia Mbbs Islam, et al.

    Objective: To find out the efficacy of Inclisiran sodium in heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) patient groups. Methods: PubMed, Embase, and Clinicaltrials.gov databases were searched for the relevant studies. Atherosclerotic parameters considered included LDL-C, total cholesterol, PCSK9, apolipoprotein-B, and non-HDL-C. Primary outcomes were the percentage difference in atherosclerotic parameters at follow-up relative to baseline values. Our study examined these primary outcomes to determine whether there is a statistically significant difference between the HeFH and HoFH groups. The risk of bias was assessed by the Cochrane risk of bias tool. Results: Analysis of four ORION clinical trials unveiled the significant difference in pooled mean differences in LDL-C (HeFH: –48.62%, HoFH: –9.12%; P < 0.05) total cholesterol (HeFH: –30.31%, HoFH: –11.50%; P < 0.05), apolipoprotein-B (HeFH: –39.97%, HoFH: –14.68%, P < 0.05), and non-HDL-C (HeFH: –44.51%, HoFH: –12.22%; P P = 0.2) between the HeFH and HoFH groups was statistically insignificant. Studies were of high quality. Conclusion: There was a significant difference in the reductions in atherosclerotic lipid parameters in heterozygous and homozygous populations after the administration of inclisiran except for the PCSK9 parameter. Further studies are needed to support this conclusion.


  • Open Access

    Exploring the Relation Between Coexisting Chronic Lymphocytic Leukemia and Lung Cancer: Two Case Reports

    by Toka Amin, Gowri Swaminathan, Muhammad Haseeb Ul Rasool, Utsow Saha, Jie Huang

    Chronic lymphocytic leukemia (CLL) is a low‐grade lymphoproliferative disorder characterized by clonal proliferation of lymphocytes. The disease is indolent but might be complicated with life‐threatening cytopenias, high‐grade transformation, or second primary malignancies (SPMs). The incidence of SPMs is higher in CLL compared to the normal population; however, the genetic association and predisposing factors linking CLL to SPMs remain unclear. Synchronous or metasynchronous CLL and lung cancer are relatively uncommon, and the relationship is rarely explored in the literature. We report two cases of a 77‐year‐old male and a 52‐year‐old female with a history of heavy smoking, both presenting with respiratory symptoms. Imaging revealed lung masses, hilar adenopathy, pleural effusions, and visceral metastasis. The first case′s pleural fluid cytology was positive for both CLL and adenocarcinoma, while the second patient was diagnosed with a biopsy from the right supraclavicular mass revealing carcinoma. In both patients, a flow cytometry of the peripheral smear confirmed the diagnosis of CLL. Both patients had a similar outcome of death due to complicated intracerebral metastatic disease with intracranial hemorrhage and vasogenic edema within 1–2 months of diagnosis. Although incompletely understood, CLL and lung cancer share some predisposing social and biological factors, of which smoking is the most evident. It is also thought that the immunocompromised state of CLL patients is a risk factor for SPMs, given qualitative and quantitative defects in almost all immune cell lines. The cytogenetic association has been suggested but has yet to be comprehensively explored. The proposed tumor factors include HER‐2/neu overexpression in lung cancer cells and Trisomy 12 in B‐cell clones, which neither of our patients had. Despite suggested links, the relationship between CLL and lung cancer needs further exploration which might offer a future benefit for anticipation and earlier detection of lung cancer in CLL patients.

  • Open Access

    Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review

    by Muhammad Taqi, Haseeb Ul Rasool, Mobeen Zaka Haider, Munjed Al Muderis

    Background: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers. Giant cells are multinucleated epithelioid cells derived from macrophages. Histologically, giant cells are also present in other pathologies of bone, e.g., aneurysmal bone cyst, chondroblastoma, giant cell granuloma, and malignant giant cell tumor, etc. Similarly, radiographic findings overlap with other osteolytic lesions, making the diagnosis and prognosis of giant cell tumor very challenging. Aims and Objectives: The purpose of this study was to explore biological and genetic markers which can be used for detection, differentiation, recurrence, and prognosis of GCTB. This will help to better understand the clinical outcome of GCTB and minimize the need for interventions. Methods: We conducted a literature search using Google, Google Scholar, PubMed, Wiley Library, Medline, Clinical trials.org, and Web of Science. Our search strategy included MeSH terms and key words for giant cell tumor and biogenetic markers from date of inception to September 2020. After excluding review articles, 246 duplicates, and non-relevant articles, we included 24 articles out of 1568 articles, summarizing the role of biogenetic markers in the prognosis of GCT. Results: P63 is 98.6% sensitive and relatively specific for GCT as compared to other multinucleated giant cells containing neoplasms. MDM2 (mouse double minute 2 homolog), IGF1 (insulin-like growth factor 1), STAT1 (signal transducer and activator of transcription 1), and RAC1 (Ras-related C3 botulinum toxin substrate 1) are associated with GCTB recurrence, and might serve as biomarkers for it. Increased expression of the proteins STAT5B, GRB2, and OXSR1 was related to a higher probability of metastasis. H3F3A and H3F3B mutation analysis appears to be a highly specific, although less sensitive, diagnostic tool for the distinction of giant cell tumor of bone (GCTB) and chondroblastoma from other giant cell-containing tumors. A neutrophil to lymphocyte ratio (NLR) > 2.70, platelet to lymphocyte ratio (PLR) > 215.80, lymphocyte to monocyte ratio (LMR) ≤ 2.80, and albumin to globulin ratio (AGR) < 1.50 were significantly associated with decreased disease-free survival (DFS) (p < 0.05). Large amounts of osteoclast-related mRNA (cathepsin K, tartrate-resistant acid phosphatase, and matrix metalloproteinase9) in GCTs (p < 0.05) are associated with the grade of bone resorption. We propose that subarticular primary malignant bone sarcomas with H3.3 mutations represent true malignant GCTB, even in the absence of a benign GCTB component. IMP3 and IGF2 might be potential biomarkers for GCT of the spine in regulating the angiogenesis of giant cell tumor of bone and predicting patients’ prognosis. Conclusions: This review study shows serological markers, genetic factors, cell membrane receptor markers, predictive markers for malignancy, and prognostic protein markers which are highly sensitive for GCT and relatively specific for giant cell tumor. MDM2, IGF1, STAT1, RAC1 are important makers in determining recurrence, while P63 and H3F3A differentiate GCT from other giant cell-containing tumors. STAT5B, GRB2, and OXSR1 are significant in determining the prognosis of GCT. Apart from using radiological and histological parameters, we can add them to tumor work-up for definitive diagnosis and prognosis.


  • Open Access

    Electrolyte disturbances in patients hospitalized for COVID-19 infection: An observational study

    by Ivan Cancarevic, Mahmoud MD Nassar, Allison Foster, Zaryab Umar, Avish Parikh, Ripon Ahammed, Lilia Shaban, Hazem Abosheaishaa, Damla Mergen, Toka Amin, et al.

    There are multiple mechanisms by which The Coronavirus-19 (COVID-19) infection can cause electrolyte abnormalities, which may not be the case for bacterial causes of pneumonia. This study aimed to assess the differences in electrolyte levels between patients suffering from COVID-19 and bacterial pneumonia. This is an original, retrospective study. Two cohorts of hospitalized patients were included, 1 suffering from COVID-19 and the other from bacterial pneumonia. Their day 1 and day 3 levels of sodium, potassium, magnesium, and phosphorus, as well as their outcomes, were extracted from the charts. Statistical analysis was subsequently performed. Mean admission levels of sodium, potassium, phosphorus, and magnesium were 135.64 ± 6.13, 4.38 ± 0.69, 3.53 ± 0.69, and 2.03 ± 0.51, respectively. The mean day 3 levels of these electrolytes were 138.3 ± 5.06, 4.18 ± 0.59, 3.578 ± 0.59, and 2.11 ± 0.64, respectively. Patients suffering from bacterial pneumonia were significantly older (N = 219, mean = 64.88 ± 15.99) than patients with COVID-19 pneumonia (N = 240, mean = 57.63 ± 17.87). Bacterial pneumonia group had significantly higher serum potassium (N = 211, mean = 4.51 ± 0.76), and magnesium (N = 115, mean = 2.12 ± 0.60) levels compared to COVID-19 group (N = 227, mean = 4.254 ± 0.60 for potassium and N = 118, mean = 1.933 ± 0.38 for magnesium). Only magnesium was significantly higher among day 3 electrolytes in the bacterial pneumonia group. No significant association between electrolyte levels and outcomes was seen. We found that COVID-19 patients had lower potassium and magnesium levels on admission, possibly due to the effect of COVID-19 on the renin–angiotensin–aldosterone system as well as patient characteristics and management. We did not find enough evidence to recommend using electrolyte levels as a determinator of prognosis, but more research is needed.


  • Open Access

    Attitudes toward COVID-19 vaccination among urogynecology patients

    by Sean Spector, Shanaya Shah, Muhammad Haseeb Ul Rasool, Elizabeth Hilt, Howard Goldstein, Jason Meade, Electra Korn, Lioudmila Lipetskaia

  • Open Access

    Osimertinib-related Pulmonary Fibrosis, A case report and review of literature

    by Muhammad Haseeb Ul Rasool, Yisrael Ferman, Brandon Ozeir, Ornela Mulkurti

    Lung cancers are the leading cause of mortality worldwide. Pulmonary malignancies are grossly divided into small-cell lung carcinoma and non-small-cell lung carcinoma. Non-small cell lung carcinoma contributes to the majority of tumor burden. The treatment regimen and subsequent prognosis for lung cancer depend on the type of cancer, the grade, and the stage. With the advancement in modern immunology and genetics, targeted treatment therapies targeted against specific genetic mutations and immune markers resulted in improved survival. Though these treatment modalities are considered to have minimal to no effect on co-existing normal tissues, there have been reports of side effects among patients on these advanced treatments. Here we present a case of 72 years old female with advanced metastatic non-small cell lung carcinoma who presented with significant deterioration of respiratory status. Initially, due to elevated inflammatory markers and fever, was treated with antibiotics. However, with worsening respiratory status despite being on appropriate antibiotics, she was started on steroids for the imaging findings suggestive of pulmonary fibrosis. Initiation of steroids resulted in rapid recovery, with the improvement of imaging findings and oxygen requirements. The patient was eventually discharged home without oxygen to follow up with hematology regarding further treatment. Osimertinib has been shown to improve progression-free survival compared to the earlier generations of EGFR TKIs, however, there are adverse effects to Osimertinib, with the most common being rash, diarrhea, and dry skin. More severe and potentially fatal, side effects like QT interval prolongation, interstitial lung disease, and drug-related pneumonitis are documented potential adverse effects as well. In all the reported cases, the removal of medication results in the improvement of pulmonary fibrosis. However, a few cases have reported successful reintroduction of Osimertinib once the fibrosis improves with no recurrence. There is a need to run blinded trials to find the association of Osimertinib with co-existent factors that can contribute to pulmonary fibrosis.

  • Open Access

    Intrapericardial Diaphragmatic Hernia Following the Convergence Procedure for Atrial Fibrillation

    by Muhammad Almas Baig, Muhammad Haseeb Ul Rasool, Arslan Ahmad, Daniel Miller, Hazem Abosheaishaa, Muhammad Burhan Majeed Rana

    This case report highlights a very rare variant of diaphragmatic hernia, namely, an intrapericardial diaphragmatic hernia, which can arise as a complication of the convergence procedure. A 77-year-old man, presenting with chronic shortness of breath and fatigue, was unexpectedly found to have herniation of the transverse colon into the pericardial cavity through a diaphragmatic-pericardial defect. The diaphragmatic defect was repaired with mesh via robotic surgery. The patient reported resolution of his symptoms at the six-month follow-up.


  • Open Access

    Kikuchi-Fujimoto Disease With Systemic Lupus Erythematosus and Systemic Sclerosis Overlap: A Unique Clinical Presentation

    by Muhammad Burhan Majeed Rana, Minahil Fatima, Iqra M. Rana, Muhammad Haseeb Ul Rasool, Hazem Abosheaishaa, Adriana Abrudescu, Sabiha Bandagi

    Kikuchi-Fujimoto Disease (KFD), or histiocytic necrotizing lymphadenitis (HNL), is a rare self-limiting disorder presenting with fever and swollen lymph nodes. It is characterized by the focal proliferation of reticular cells, the presence of nuclear debris, and histiocytes. In advanced cases, it can present with hepato-splenomegaly and generalized lymphadenopathy. Historically, it has been associated with viral infections, as it frequently was found to be associated with upper respiratory symptoms. Alternative explanations include the immune response of T-cells leading to alteration in CD8-positive T-cell-mediated cell apoptosis. It is also speculated that KFD can be associated with rheumatological autoimmune diseases. We present a case of a 21-year-old African American female with a known diagnosis of systemic lupus erythematosus (SLE)-systemic sclerosis (SS) overlap presented with febrile lymphadenopathy and was diagnosed to have HNL on histological exam of lymph node biopsy.


  • Open Access

    A Tumor in Disguise: Gallbladder Tumor Presenting as Hepatic Abscesses

    by Muhammad Haseeb Ul Rasool, Utsow Saha, Arshia K. Sethi, Muhammad Adnan, Nahian Rabby, Muhammad Adnan Khan

    Gallbladder tumors are the most common tumors of the biliary tract. They are rare but clinically aggressive tumors found either as metastatic disease or occasionally detected upon the histopathological assessment of cholecystectomy biopsy. Adenocarcinoma is the most common phenotype of gallbladder cancer, which can be mild to moderately differentiated. Other malignant phenotypes include mucinous adenocarcinoma, signet cell, small cell, papillary adenocarcinoma, intestinal type adenocarcinoma, and undifferentiated carcinoma. The rarity of the disease makes the diagnosis extremely difficult in the initial phases. Liver abscesses are extremely rare and scarcely reported presentation of gallbladder cancer, with only a handful reported cases. It is speculated that the development of hepatic abscesses depicts direct involvement of hepatic parenchyma, development of associated necrosis, and superimposed bacterial infection evolving to an abscess. Gallbladder perforations are rare and potentially life-threatening complications of any gallbladder disease. Increased intraluminal pressure leads to mural necrosis, emphysematous changes in the wall, and vascular compromise which leads to gallbladder wall necrosis leading to perforation. Gallbladder tumors are exceedingly notorious for poor outcomes with very limited survival. Here, we present a case of a 69-year-old male who initially presented with impending perforation of the gallbladder with multiple hepatic masses, which were thought to be metastatic deposits. However, on biopsy, he was found to have multiple hepatic abscesses due to localized necrosis. Further workup revealed that the patient had an advanced metastatic gallbladder tumor that had passed the stage of tumor resection. Gallbladder perforations are classified according to Niemeier's classification. Our patient had a type II perforation which resulted in a hepatic abscess.